Mise à jour 2014 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France

Penault‐Llorca, Frédérique; Vincent‐Salomon, Anne; MacGrogan, Gaëtan; Roger, Pascal; Treilleux, Isabelle; Valent, Alexander; Mathieu, Marie‐Christine; Antoine, Martine; Becette, Véronique; Bor, Catherine; Brabencová, Eva; Charafe-Jauffret, Emmanuelle; Chenard, Marie–Pierre; Dauplat, Marie-Mélanie; Delrée, P.; Devouassoux, Mojgan; Fiche, Maryse; Fondrevelle, Marie-Eve; Fridman, Viviana; Garbar, Christian; Genin, Pascal; Ghnassia, Jean-Pierre; Haudebourg, Juliette; Laberge, Sophie; Loussouarn, Delphine; Maran-Gonzalez, Aurélie; Marcy, M.; Michenet, Patrick; Poulet, Bruno; Sagan, Christine; Trassard, Martine; Verrièle, Véronique; Arnould́, Laurent; Lacroix-Triki, Magali

doi:10.1016/j.annpat.2014.08.018

Cited by 28 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Les études de Iwaya, Puri et Vo, avaient en revanche montré l’absence d’une association entre le grade tumoral et l’expression de CD10 [ 11 , 14 , 16 ]. En ce qui concerne les récepteurs hormonaux, plusieurs études avaient montré que l’expression stromale de CD10 était corrélée à la négativité de RE, comme dans notre série (p=0,001) [ 13 - 16 , 18 , 19 , 23 , 24 ]. Certaines études avaient montré la présence d’une corrélation significative entre l’expression de CD10 et la négativité des RP [ 12 , 13 , 16 , 19 ].…”

Section: Discussionunclassified

Expression stromale de CD10 dans les cancers du sein: marqueur de mauvais pronostic

Bacha¹,

Amor²,

Farhat³

et al. 2020

Pan Afr Med J

View full text Add to dashboard Cite

Introduction les marqueurs du stroma carcinomateux comme la classe de différenciation 10 (CD10) seraient corrélés à un potentiel invasif et métastatique de plusieurs types de cancers en favorisant la croissance tumorale et l’apparition de métastases. Pour les carcinomes mammaires, sa valeur pronostique reste encore controversée avec des résultats discordants. Les objectifs de notre étude étaient d’étudier l’expression stromale de CD10 dans les carcinomes mammaires et d’évaluer la valeur pronostique de cette expression. Méthodes notre étude était rétrospective, descriptive et pronostique. Elle avait intéressé 57 patientes porteuses de carcinomes invasifs de type non spécifique, colligés au service d’anatomie pathologique de l’hôpital Mongi Slim, sur une période de 38 mois. L’étude de CD10 a été réalisée par immunohistochimie et son interprétation était basée sur un score semi-quantitatif en trois catégories avec des seuils de 10 et 30%. Résultats l’âge moyen de nos patientes était de 56,4 ans. Vingt-huit patientes (49%) avaient un marquage stromal de CD10, la moitié était de score 1 (faible) et l’autre moitié de score 2 (fort). Ce marquage diminuait significativement la survie sans récidives (p=0,001). Il n’y a en revanche pas d’influence sur la survie globale (p=0,84). L’étude de corrélation avait montré que l’expression stromale de CD10 était significativement corrélée à 12 facteurs de mauvais pronostic dans les cancers du sein. Conclusion l’expression de CD10 dans le stroma des carcinomes mammaires invasifs constitue un facteur de mauvais pronostic, prédictif d’une faible survie sans récidives et est associée à un potentiel invasif et métastatique élevé.

show abstract

Section: Discussionunclassified

Expression stromale de CD10 dans les cancers du sein: marqueur de mauvais pronostic

Bacha¹,

Amor²,

Farhat³

et al. 2020

Pan Afr Med J

View full text Add to dashboard Cite

show abstract

“…A tumor was considered ERBB2-positive by immunohistochemistry if it scored 3 with uniform intense membrane staining of greater than 10% of invasive tumor cells. Tumors scoring 2 were considered to be equivocal for ERBB2 protein expression and were tested by fluorescence in situ hybridization for ERBB2 gene amplification [37]. …”

Section: Methodsmentioning

confidence: 99%

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas

et al. 2016

Self Cite

View full text Add to dashboard Cite

ERBB2 and ERBB3 somatic gain-of-function mutations, which may be targeted by anti-ERBB2 therapies, were reported by high-throughput sequencing studies in 1% and 2% of invasive breast cancers respectively. Our study aims to determine ERBB2 and ERBB3 mutations frequencies in grade 3 and/or ERBB2-positive invasive lobular breast carcinomas (ILC). All the 529 ILC surgically-excised registered at Institut Curie in the years 2005 to 2008 were reviewed. Thirty-nine grade 3 ERBB2-negative ILC and 16 ERBB2-positive ILC were retrieved and subjected to Sanger sequencing of the ERBB2 and ERBB3 activation mutation hotspots (ERBB2: exons 8, 17, 19, 20, 21; ERBB3: exons 3, 6, 7, 8). Among the 39 grade 3 ERBB2-negative ILC, six tumors were found to have at least one detectable ERBB2 activating mutation (incidence rate: 15%, 95%CI [4%-27%]). No ERBB2 mutation was found among the 16 ERBB2-positive ILC. No ERBB3 mutation was found in any of the 55 ILC. ERBB2 mutations were statistically associated with solid ILC features (p=0.01). Survival analyses showed no significant prognostic impact of ERBB2 mutations. Our study demonstrates that high grade ERBB2-negative ILC display a high frequency of ERBB2 mutations, and should be subjected to systematic genetic screening.

show abstract

“…For cases with an IHC score of 2, we looked for HER2 amplification using in situ hybridisation technologies (Penault-Llorca et al , 2014). Exclusion criteria were clinical T4, bilateral disease, neoadjuvant treatment and any personal history of cancer.…”

Section: Methodsmentioning

confidence: 99%

Axillary lymph node micrometastases decrease triple-negative early breast cancer survival

et al. 2016

View full text Add to dashboard Cite

Background:Triple-negative breast cancers (TNBCs) are the most deadly form of breast cancer (BC) subtypes. Axillary lymph node involvement (ALNI) has been described to be prognostic in BC taken as a whole, but its prognostic value in each subtype is unclear. We explored the prognostic impact of ALNI and especially of small size axillary metastases in early TNBCs.Methods:We analysed in this multicentre study all patients treated for early TNBC in 12 French cancer centres. We explored the correlation between clinicopathological data and ALNI, with a specific focus on the dichotomisation between macrometastases and occult metastases, which is defined as the presence of isolated tumour cells or micrometastases. The prognostic value of ALNI both in terms of disease-free survival (DFS) and overall survival (OS) was also explored.Results:We included 1237 TNBC patients. Five-year DFS and OS were 83.7% and 88.5%, respectively. The identified independent prognostic features for DFS were tumour size >20 mm (hazard ratio (HR)=1.86; 95% CI: 1.11–3.10, P=0.018), lymphovascular invasion (HR=1.69; 95% CI: 1.21–2.34, P=0.002) and ALNI both in case of macrometastases (HR=1.97; 95% CI: 1.38–2.81, P<0.0001) and occult metastases (HR=1.72; 95% CI: 1.1–2.71, P=0.019). DFS and OS were similar between tumours with occult metastases and macrometastases. Tumours presenting at least two pejorative features (out of ALNI, lymphovascular invasion and large tumour size) displayed a significantly poorer DFS in both the training set and validation set, independently of chemotherapy administration. Tumours with no more than one of the above-cited pejorative features had a 5-year OS of ⩾90% vs 70% for other cases (P<0.0001).Conclusions:Axillary lymph node involvement is a key prognostic feature for early TNBC when isolated tumour cells were identified in lymph nodes. This impact is independent of chemotherapy use.

show abstract

Mise à jour 2014 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France

Cited by 28 publications

References 17 publications

Expression stromale de CD10 dans les cancers du sein: marqueur de mauvais pronostic

Expression stromale de CD10 dans les cancers du sein: marqueur de mauvais pronostic

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas

Axillary lymph node micrometastases decrease triple-negative early breast cancer survival

Contact Info

Product

Resources

About